Drug Approval | March 31, 2026
ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
The decision is based on the phase 3 DESTINY-Breast11 trial
The decision is based on the phase 3 DESTINY-Breast11 trial
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
Subscribe To Our Newsletter & Stay Updated
